Peritoneal Carcinomatosis in Digestive Neuroendocrine Neoplasms: Complications and Response to Therapy Abstract #1577

Introduction: Peritoneal carcinomatosis (PC) is present in 10-30% of digestive neuroendocrine neoplasms (DNENs), affecting prognosis and quality of life with recurrent abdominal pain and bowel obstruction
Aim(s): to describe in a consecutive series of DNENs with PC the evolution of PC and correlation to therapy
Materials and methods: retrospective analysis of pts with sporadic DNENs diagnosed in 1993-2014 with at least 12-month follow-up after PC diagnosis
Conference: 13th Annual ENETS conference (2016)
Category: Epidemiology/Natural history/Prognosis - Prognosis
Presenting Author: MD, PhD Elettra Merola

To read results and conclusion, please login ...

Further abstracts you may be interested in

#1006 The Use of Endoluminal Stents to Overcome Vascular Obstruction Arising from Mesenteric and Retroperitoneal Neuroendocrine Metastases
Introduction: Gastroenteropancreatic neuroendocrine tumors (GEP-NET) often metastasise to lymph nodes. Nodal metastases from neuroendocrine tumors in the distal small intestine commonly (>50%) develop in the mesentery and are often centred at the mesenteric root surrounding the major vessels supplying the bowel. Compression of these vessels, by the nodes or associated fibrosis, can lead to severe symptoms such as pain (secondary to bowel ischaemia ), ascites (from superior mesenteric vein obstruction) and bowel perforation. In view of the often indolent nature of GEP-NET, symptoms from lymph node masses can persist for years, causing significant morbidity and early mortality.
Conference: 11th Annual ENETS Conference (2014)
Category: Clinical cases/reports
Presenting Author: Dr Alan Anthoney
#1474 Curative Resection in Digestive Neuroendocrine Neoplasms: Recurrence-free Survival Rate and Definition of a Risk Score for Recurrence
Introduction: Surgery with radical intent is the only curative option for digestive neuroendocrine neoplasms (DNENs), but clinical practice shows disease-free pts recurring even after years
Conference: 13th Annual ENETS conference (2016)
Category: Surgical treatment
Presenting Author: MD, PhD Elettra Merola
#2197 Tumor Necrosis of Primary Malignancy Affects Survival and Outcome in Patients with Liver Metastases from Neuroendocrine Tumors
Introduction: Reliable biomarkers represent a crucial unmet need in the management of neuroendocrine tumors. Tumor necrosis has been suggested to have a prognostic value in selected solid tumors but is not included in established WHO NET Grading Systems. However, little is known regarding the influence of tumor necrosis on tumor progression and prognosis in patients with liver metastasis from neuroendocrine tumors.
Conference: 15th Annual ENETS conference (2018)
Category: Biomarkers
Presenting Author: Dr. med. Georgi Atanasov
#423 Case Report : A Rare Cause of Retroperitoneal Fibrosis Responding to Steroids
Introduction: Retroperitoneal fibrosis is a rare inflammatory disease. Neuroendocrine tumors are a heterogenous group that arise from enterochromaffin cells, most commonly in the gastrointestinal tract. Their capacity to secrete hormones, five HT, tachykinins etc, are responsible for symptoms known as carcinoid syndrome. However NETS, particularly arising from the midgut, can cause fibrosis. This can result in bowel obstruction, but also cause fibrosis in the retroperitoneum, lungs and cardiac valvular fibrosis.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Dr Dalvinder Mandair
Authors: Mandair D, Mangat K, Malaki M, Shah T, ...
#1282 Peritoneal Metastases from Gastroenteropancreatic Neuroendocrine Tumors: Frequency, Treatment and Prognosis
Introduction: Data on peritoneal metastases (PM) in patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are scarce.
Conference: 13th Annual ENETS conference (2016)
Category: Epidemiology/Natural history/Prognosis - Descriptive epidemiology
Presenting Author: MD Ariana Madani